Use of zoledronic acid in the treatment of Gorham's disease

Avelar, Rafael Linard; Martins, Valber Barbosa; Antunes, Antônio Azoubel; Neto, Patrício José de Oliveira; Andrade, Emanuel Sávio de Souza

doi:10.1016/j.ijporl.2009.12.007

Cited by 47 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lehmann et al reported a case treated with biphosphonates for 17 years with good response (14). Zoledronic acid treatment has been effective with no recurrence in young people (15,16). Because of its antiangiogenic properties interferon alfa could be useful in GorhamStout disease with documented vessel proliferation with extended lymph-hemangiomatosis (13,17).…”

Section: Discussionmentioning

confidence: 99%

Two cases of Gorham-Stout disease with good response to zoledronic acid treatment

Brance¹,

Castiglioni

Cóccaro

et al. 2017

ccmbm

View full text Add to dashboard Cite

SummaryGorham-Stout disease -also called vanishing bone syndrome -is a rare bone disease characterized by a progressive intra-osseous proliferation of non-neoplastic vascular tissue resulting in massive osteolysis. Here, we report two clinical cases of Gorham-Stout disease. Case 1: a 56-year-old woman with 20 years of history of pain and swell in elbows, ankles and wrist. Then she was diagnosed as systemic lupus erythematosus (SLE) with glomerulonephritis type III. After other pathologies were ruled out Gorham-Stout disease was diagnosed. Intravenous zoledronic acid (5 mg) was indicated and after third infusion a progressive improvement of pain, mobility and daily activities were observed. Case 2: a 70-years-old man with a history of pain and limited motion in the left shoulder without X-ray abnormality. Six months later pathological fracture in the left humerus occurred and after ruled out other pathologies Gorham-Stout disease was diagnosed. Intravenous zoledronic acid (5 mg) was indicated and a good response was observed after the first infusion. Nowadays just over 200 cases were reported. Gorham-Stout disease was reported in different bones, at different age presentation and severe physical deformities, disabilities, and life-threatening complications can occur. Two cases of Gorham-Stout disease with good response to zoledronic acid was reported in this article.

show abstract

Section: Discussionmentioning

confidence: 99%

Two cases of Gorham-Stout disease with good response to zoledronic acid treatment

Brance¹,

Castiglioni

Cóccaro

et al. 2017

ccmbm

View full text Add to dashboard Cite

show abstract

“…Мнения о роли остеокластов в деструкции костной ткани при GSD противоречивы: ряд исследователей подтверждает их высокую активность [1,5,6,18,22,26,32,36,42,44,48,50], другие отмечают их отсутствие в оча-гах остеолиза [12,13,21,45,51]. При-чина такого противоречия, возмож-но, обусловлена проведением гисто-логического исследования на разных стадиях процесса [4].…”

Section: рисunclassified

“…Лучевую терапию при-меняют как в виде монотерапии, так и в комплексе с хирургическим лече-нием [8,9,11], указывая на ее клини-ческую эффективность в 75 % случа-ев локальных поражений при общей дозе облучения 36-45 Гр фракциями по 2 Гр [8,9,33,35]. Из медикаментоз-ных средств используют бисфосфо-наты и интерферон-альфа-2в, причем как изолированно, так и совместно [1,15,16,18,25,31,42,54]. Сообща-ется также об успешном применении бевацизумаба [15], пропранолола [38] и кальцитонина [40], однако такие сообщения касаются отдельных наблюдений.…”

Section: рисunclassified

A Rare Variant of Angiogenic Vertebral Body Destruction in a Child: Gorham’s Disease?

Мушкин¹,

Евсеев²,

Николаев³

et al. 2018

Hir. pozvonoč.

View full text Add to dashboard Cite

“…8 No obstante, el interferón alfa-2b tiene actividad antiangiogénica e inmunomoduladora, que disminuye los niveles circulatorios de la IL-6 y, por ende, inhibe la proliferación anómala de vasos sanguíneos. 9 Además, los bifosfonatos han demostrado ser beneficiosos para esta patología. En esta enfermedad, se crea un desbalance entre la actividad osteoblástica y osteoclástica, por lo que los bifosfonatos, al incrementar la apoptosis de los osteoclastos y disminuir su actividad, estabilizan el progreso del cuadro.…”

unclassified

“…En esta enfermedad, se crea un desbalance entre la actividad osteoblástica y osteoclástica, por lo que los bifosfonatos, al incrementar la apoptosis de los osteoclastos y disminuir su actividad, estabilizan el progreso del cuadro. 9 …”

unclassified